Diabetic Macular Edema

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.

Based on personal clinical experience, Arshad Khanani, MD, explains his current approach to treating wet age-related macular degeneration with anti-VEGF therapy, with special considerations for appropriate dosage and timing of injections, and describes how he assesses patient response to therapy.

Dr Arshad Khanani describes the role of anti-VEGF therapy for wet age-related macular degeneration and elaborates on factors that impact treatment selection and sequencing in a patient’s continuum of care.

Strategies that can be used to screen and confirm a diagnosis of age-related macular degeneration, as well as monitor patients to optimize care.

Arshad Khanani, MD, defines age-related macular degeneration as it relates to vision loss, highlighting the ways the condition may present in patients and its impact on quality of life.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

The company plans to submit the data to the FDA and EMA for consideration of the injectable bispecific antibody's regulatory approval for the treatment of both conditions.

Low and moderate dosing shows the most potential in preventing AMD for patients with diabetes.

Patients treated with the bispecific antibody at fixed intervals of 16 weeks achieved visual acuity outcomes comparable to 8-week interval treatment of aflibercept.

Primate model studies show the procedure can be done safely and without losing eye function. Which patients may benefit first?

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.

A new health care pathway could be safe to implement in clinical practice.

A large population study in Taiwan found regular use of aspirin for prevention of cardiac events increased risk for age-related macular degeneration.

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.

SFChT in treatment-naïve eyes was positively associated with eGFR and diabetic retinopathy grade.

In a comparison with manual human grading, investigators find machine learning model produced no statically significant differences in Dice coefficients.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.

A total of 115 of 200 examined eyes had some form of diabetic retinopathy in data presented at the ASRS 2020 virtual meeting.

In research presented at ASRS 2020, investigators found 56% of patients with PDR had a DME code, with a sensitivity of 85%.

A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.

The specialty is on the precipice of advancement. What gets it over the hurdle?

In a study presented at ASRS 2020, investigators find an improvement in DRSS is not correlated with a change in best corrected visual acuity.

Steroids are often prescribed for diabetic macular edema following ineffectiveness of laser photocoagulation and anti-VEGF.

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.